Experimental Treatment of Ebola Virus Disease with Brincidofovir
| dc.contributor.author | Dunning, J | |
| dc.contributor.author | Kennedy, SB | |
| dc.contributor.author | Antierens, A | |
| dc.contributor.author | Whitehead, J | |
| dc.contributor.author | Ciglenecki, I | |
| dc.contributor.author | Carson, G | |
| dc.contributor.author | Kanapathipillai, R | |
| dc.contributor.author | Castle, L | |
| dc.contributor.author | Howell-Jones, R | |
| dc.contributor.author | Pardinaz-Solis, R | |
| dc.contributor.author | Grove, J | |
| dc.contributor.author | Scott, J | |
| dc.contributor.author | Lang, T | |
| dc.contributor.author | Olliaro, P | |
| dc.contributor.author | Horby, PW | |
| dc.date.accessioned | 2016-09-15T15:09:39Z | |
| dc.date.available | 2016-09-15T15:09:39Z | |
| dc.date.issued | 2016-09-09 | |
| dc.date.submitted | 2016-09-12 | |
| dc.identifier.citation | Experimental Treatment of Ebola Virus Disease with Brincidofovir., 11 (9):e0162199 PLoS ONE | en |
| dc.identifier.issn | 1932-6203 | |
| dc.identifier.pmid | 27611077 | |
| dc.identifier.doi | 10.1371/journal.pone.0162199 | |
| dc.identifier.uri | http://hdl.handle.net/10144/618652 | |
| dc.description.abstract | The nucleotide analogue brincidofovir was developed to prevent and treat infections caused by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect against Ebola virus, brincidofovir was included in the World Health Organisation list of agents that should be prioritised for clinical evaluation in patients with Ebola virus disease (EVD) during the West African epidemic. | |
| dc.language | ENG | |
| dc.language.iso | en | en |
| dc.publisher | Public Library of Science | en |
| dc.rights | Published by Public Library of Science, [url]http://www.plosone.org/[/url] Archived on this site by Open Access permission | en |
| dc.title | Experimental Treatment of Ebola Virus Disease with Brincidofovir | en |
| dc.identifier.journal | PloS One | en |
| refterms.dateFOA | 2019-03-04T12:50:14Z | |
| html.description.abstract | The nucleotide analogue brincidofovir was developed to prevent and treat infections caused by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect against Ebola virus, brincidofovir was included in the World Health Organisation list of agents that should be prioritised for clinical evaluation in patients with Ebola virus disease (EVD) during the West African epidemic. |
